Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer

Digestive and Liver Disease

Volumn 46, Issue 3, 2014, Pages 283-286

  Touchefeu, Yann ^a   Archambeaud, Isabelle ^a   Landi, Bruno ^b   Lièvre, Astrid ^c   Lepère, Céline ^b   Rougier, Philippe ^b   Mitry, Emmanuel ^c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b HÔpital européen Georges Pompidou ^*  (France)

^c INSTITUT CURIE   (France)

Author keywords

Chemotherapy; Dysphagia; Oesophageal neoplasms; Stents

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DYSPHAGIA; ESOPHAGUS CANCER; ESOPHAGUS OBSTRUCTION; FEMALE; FOOD INTAKE; GASTROESOPHAGEAL JUNCTION CANCER; GASTROESOPHAGEAL REFLUX; HUMAN; INTERMETHOD COMPARISON; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERFORATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RETROSTERNAL PAIN; SCORING SYSTEM; SELF EXPANDING STENT; STOMACH CANCER; TUMOR RECURRENCE; UNIVERSITY HOSPITAL;

CHEMOTHERAPY; DYSPHAGIA; OESOPHAGEAL NEOPLASMS; STENTS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEGLUTITION DISORDERS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; ESOPHAGEAL STENOSIS; ESOPHAGOGASTRIC JUNCTION; ESOPHAGOSCOPY; FEMALE; FLUOROURACIL; GASTROSCOPY; HUMANS; LEUCOVORIN; MALE; METALS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STENTS;

EID: 84893774636     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.10.012     Document Type: Article

References (15)

1. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000. The global picture. European Journal of Cancer 2001, 37(Suppl. 8):S4-S66.
2. Faivre J., Forman D., Esteve J., et al. Survival of patients with oesophageal and gastric cancers in Europe. EUROCARE Working Group. European Journal of Cancer 1998, 34:2167-2175.
3. Harrison L.E. Is esophageal cancer a surgical disease?. Journal of Surgical Oncology 2000, 75:227-231.
4. Ross W.A., Alkassab F., Lynch P.M., et al. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointestinal Endoscopy 2007, 65:70-76.
5. Shenfine J., McNamee P., Steen N., et al. A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technology Assessment 2005, 9. iii, 1-121.
6. Ilson D.H., Forastiere A., Arquette M., et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer Journal 2000, 6:316-323.
7. Ilson D.H., Saltz L., Enzinger P., et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. Journal of Clinical Oncology 1999, 17:3270-3275.
8. Atkinson M., Ferguson R., Ogilvie A.L. Management of malignant dysphagia by intubation at endoscopy. Journal of the Royal Society of Medicine 1979, 72:894-897.
9. Mitry E., Taieb J., Artru P., et al. Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. Annals of Oncology 2004, 15:765-769.
10. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 2000, 18:2938-2947.
11. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
12. Taieb J., Artru P., Baujat B., et al. Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. European Journal of Cancer 2002, 38:661-666.
13. Homs M.Y., Steyerberg E.W., Eijkenboom W.M., et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004, 364:1497-1504.
14. Hanna W.C., Sudarshan M., Roberge D., et al. What is the optimal management of dysphagia in metastatic esophageal cancer?. Current Oncology 2012, 19:e60-e66.
15. Conio M., Repici A., Battaglia G., et al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. American Journal of Gastroenterology 2007, 102:2667-2677.